In patients with advanced-stage TNBC, monotherapy with PD-1 or PD-L1 antibodies has limited efficacy and might only benefit a small portion of patients [17]; chemo-immunotherapy approaches have improved tumor progression-free and overall survival, but these trials have yet to undergo detailed biomarker analysis [5]. The gene discussed is PDCD1; the disease is neoplasm.